HS
CATX icon

HighVista Strategies’s Perspective Therapeutics CATX Stock Holding History

HighVista Strategies’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-138,350
Closed -$476K – 152
2025
Q2 		$476K Hold
138,350
– – 0.17% 128
2025
Q1 		$295K Hold
138,350
– – 0.11% 140
2024
Q4 		$441K Hold
138,350
– – 0.16% 125
2024
Q3 		$1.85M Buy
138,350
+24,800
+22% +$330K 0.64% 55
2024
Q2 		$1.13M Buy
+113,550
New +$1.64M 0.41% 97

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HighVista Strategies's CATX Position: Q3 2025 in Review

HighVista Strategies sold out of Perspective Therapeutics (CATX) in Q3 2025, closing a stake of 138,350 shares — an estimated $476K sold.

HighVista Strategies first reported a position in CATX in Q2 2024 and held it in 5 quarters. The position peaked at $1.85M in Q3 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q3 2025.

  • HighVista Strategies reported no remaining Perspective Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HighVista Strategies sold 138,350 Perspective Therapeutics shares in Q3 2025, an estimated $476K.
  • HighVista Strategies first reported a position in Perspective Therapeutics in Q2 2024 and held it in 5 quarters.
  • HighVista Strategies's Perspective Therapeutics position peaked at $1.85M in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2025.

Based on HighVista Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.